Lantus® SoloStar Pens for Once‑Daily Basal Insulin Therapy

What Lantus® Is and How It Works

Lantus® (insulin glargine 100 units/mL) is a long-acting basal insulin for subcutaneous use. The SoloStar prefilled pen delivers steady insulin over 24 hours. It helps control fasting blood glucose in adults with type 1 or type 2 diabetes, and in children 6 years and older with type 1 diabetes. Many patients compare Lantus Solostar Pens price options and prefer Canadian pharmacy access for value. You can order Lantus Solostar Pens through our site, including for those paying cash. We also serve people seeking Lantus Solostar Pens without insurance.

YouDrugstore is a licensed Canadian pharmacy headquartered in Manitoba; prescriptions are reviewed by licensed pharmacists before dispensing.

We source through licensed, vetted international partner pharmacies so you receive authentic brand medications, broad selection, and competitive pricing.

Insulin glargine forms microprecipitates in subcutaneous tissue that release insulin slowly. This creates a flat, peakless profile for about 24 hours. Lantus® is taken once daily at the same time each day as background insulin. It is not for intravenous use, not for insulin pumps, and must not be mixed or diluted with other insulins. It is not appropriate for treating diabetic ketoacidosis.

Dosage and Usage

• Use once daily at the same time. Follow prescriber directions for dose and titration.
• When starting basal insulin, dose adjustments often occur every few days based on fasting glucose trends.
• When switching from once-daily NPH insulin, many start unit‑for‑unit at the next dose. Closer monitoring is required.
• When switching from twice-daily NPH, an initial Lantus® dose may be lower to reduce hypoglycemia risk.
• Inject subcutaneously in the abdomen, thigh, or upper arm. Rotate sites to reduce lipodystrophy.
• Missed dose: take as soon as remembered on the same day if feasible. If near the next dose, seek professional guidance and avoid double dosing.
• Do not share pens or needles. Sharing can transmit infections.

• Prepare the SoloStar device: check the label and insulin appearance (should be clear and colorless).
• Attach a new sterile needle and remove both caps.
• Prime the pen per the Instructions for Use (for example, 2 units) until a drop appears at the tip.
• Dial the prescribed dose. Insert the needle at 90 degrees into fatty tissue.
• Press and hold the injection button fully. Keep the needle in place for 10 seconds to ensure full dose delivery.
• Remove and safely discard the needle in a sharps container. Replace the pen cap.

• Storage, unopened pens: refrigerate at 2–8 °C (36–46 °F). Do not freeze. Keep away from heat and light.
• In‑use pen: store below 25 °C (77 °F) for up to 28 days, or as labeled. Do not refrigerate a pen currently in use if local labeling advises room temperature only.
• Do not use if frozen, past expiry, or if solution is cloudy, colored, or contains particles.
• Travel: carry pens in an insulated bag with cold packs, not in direct contact with ice. Do not leave in a parked car.
• Keep a backup pen, extra needles, and a small sharps container when traveling. Carry supplies in your hand luggage.
• During shipment, products are packed with prompt, express, cold‑chain handling to protect stability.

Benefits and Savings

Lantus® provides steady, 24‑hour basal coverage with a low day‑to‑day variability profile. It helps lower fasting glucose and A1C when used as directed. Compared with NPH insulin, studies show less nocturnal hypoglycemia and once‑daily convenience for many patients. The SoloStar device is prefilled, easy to hold, and dials by 1‑unit increments. Each pen contains 300 units; many packs include five pens.

Ordering from a Canadian online pharmacy can reduce costs. Typical savings reach 60–80% versus usual U.S. prices. Patients paying without insurance often find the monthly cost more manageable, especially with multi‑pack orders. Reorder reminders can help you stay supplied before the 28‑day in‑use period ends.

To explore extra savings, visit our Lantus Solostar Pens coupon offers.

Side Effects and Safety

• Hypoglycemia (shakiness, sweating, hunger, headache, confusion)
• Injection‑site reactions (redness, pain, irritation)
• Lipodystrophy or skin thickening at injection sites
• Edema or fluid retention
• Mild weight gain
• Rash or pruritus
• Allergic reactions

Serious risks include severe hypoglycemia, which can lead to seizures or loss of consciousness. Monitor more closely when doses change or when activity or meals vary. Combining with prandial insulin or sulfonylureas increases hypoglycemia risk; dose adjustments may be needed. Rare systemic hypersensitivity can occur. Using thiazolidinediones with insulin may cause fluid retention and worsen heart failure. Discuss use in renal or hepatic impairment, and in pregnancy or breastfeeding.

Onset Time

Lantus® begins working within about 1–2 hours after injection and has no prominent peak. Most patients see fasting glucose improve over several days as basal dosing stabilizes. A1C changes generally become clear after 8–12 weeks of consistent therapy and follow‑up. Weight changes, if any, tend to emerge gradually over months.

Compare With Alternatives

Insulin detemir (Levemir) is another long‑acting basal insulin with once‑ or twice‑daily dosing. Some patients prefer detemir’s profile; others prefer the flatter 24‑hour coverage of glargine. Your prescriber considers dose timing, hypoglycemia patterns, and lifestyle when selecting a basal insulin.

Insulin degludec (Tresiba) is an ultra‑long‑acting alternative with a duration that exceeds 24 hours and flexible dosing windows. It may suit those needing even more dosing flexibility. Cost and insurance coverage can guide the choice between glargine and degludec.

For those who prefer vials and syringes, a Lantus® Vial offers the same insulin in a different format. Mealtime control often uses rapid‑acting insulin; options include a Humalog® Vial or cartridges. Discuss how basal and bolus options can be combined to match meals and activity.

Combination Therapy

• With rapid‑acting insulin at meals (basal‑bolus therapy): adjust doses to carbohydrate intake and glucose results.
• With metformin in type 2 diabetes: often retains metformin while titrating basal insulin.
• With SGLT2 inhibitors or DPP‑4 inhibitors: may support additional A1C reduction.
• With GLP‑1 receptor agonists: can reduce required basal dose in some patients.
• When used with sulfonylureas or prandial insulin, consider dose reductions to lower hypoglycemia risk.

Patient Suitability and Cost-Saving Tips

Lantus® is suitable for adults with type 1 or type 2 diabetes who need basal insulin, and for children 6 years and older with type 1 diabetes. It is not for treating diabetic ketoacidosis, not for intravenous use, and not for insulin pump systems. Avoid use if allergic to insulin glargine or any component of the formulation.

Patients with frequent hypoglycemia or unawareness, advanced liver or kidney disease, or heart failure on thiazolidinediones need careful supervision. Rotate injection sites and avoid areas of skin thickening or scarring. Report any severe allergic symptoms, persistent injection‑site reactions, or unexplained edema.

To manage costs, consider multi‑month supplies when your prescription allows, as bulk promotions can lower per‑month costs. Set a calendar reminder to reorder before your last in‑use pen expires. Those paying cash can still access fair Lantus Solostar pricing, and many compare deals for Lantus Solostar Pens without insurance across providers before deciding.

Authoritative Sources

Lantus consumer site (Sanofi)

Health Canada Product Monograph: Lantus (insulin glargine)

FDA Prescribing Information: Lantus (insulin glargine) injection

Order Lantus® from YouDrugstore: add to cart, upload your prescription, and we ship with prompt, express, cold‑chain handling.

This content is educational and does not replace advice from your doctor, pharmacist, or diabetes care team.